Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.73 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.73 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.73 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.69 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.69 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | FABP3 | P05413 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532168 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532171 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 0.99 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263792-A1 | METHODS FOR THE IDENTIFICATION AND TREATMENT OF SEVERE FORMS OF COVID-19 | GENUITY SCIENCE, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4107629-B1 | SENSOR STORAGE SYSTEM | RAYTHEON CO (US) | 2025-08-13 | — | — | EP | claimed |
| CN-120197269-A | Earthquake-resistant toughness evaluation method for underground station structure | 南京工业大学 | 2025-06-24 | — | — | CN | claimed |
| US-12309700-B2 | Systems and methods for connected mode discontinuous reception on/off determinations | APPLE INC. (US) | 2025-05-20 | — | — | US | claimed |
| CN-119979719-A | Gene-based universal detection method for pluripotent stem cell residues | 中国食品药品检定研究院 | 2025-05-13 | — | — | CN | claimed |
| EP-4538829-A2 | METHOD, APPARATUS AND SYSTEM FOR RENDERING AN INFORMATION BEARING FUNCTION OF TIME | Parkervision, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| CN-118075309-B | Lightweight DDS (direct digital synthesizer) middleware and application thereof in AUTOSAR Classic platform | 同济大学 | 2025-04-08 | — | — | CN | claimed |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | CureVac SE (DE) | 2025-03-13 | — | — | US | claimed |
| CN-119544622-A | TSN-based DDS data distribution method, computing device and storage medium | 安捷中科(北京)数据科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119520602-A | Processing method and device of data distribution service, electronic equipment and storage medium | 北京罗克维尔斯科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-114286429-A | Communication method and device | 华为技术有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114173640-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-114051390-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-02-15 | — | — | CN | claimed |
| WO-2022021033-A1 | INFORMATION PROCESSING METHOD AND APPARATUS, AND COMMUNICATION DEVICE AND STORAGE MEDIUM | 北京小米移动软件有限公司 | 2022-02-03 | — | — | WO | claimed |
| CN-114007499-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-114007505-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-114007504-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-114007495-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-113993452-A | Digital biomarkers | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113971613-A | Data processing method and system | 中国科学技术大学 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | NSUN3, SARNP, TRDMT1 | P2RY10 4536/4885GPR34 4585/4885GPR174 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.